FDA Grants IND For Pro-Pharmaceuticals’ DAVANAT® To Treat Breast Cancer Patient
Pro-Pharmaceuticals, Inc. (Amex: PRW), today announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of DAVANAT® in combination with 5-FU to treat a breast cancer patient at the Brown Cancer Center in Louisville, Kentucky. DAVANAT® also is being administered in Phase II clinical trials for first-line treatment of colorectal and biliary cancer patients.
More: continued here
Filed under: Breast Cancer on September 8th, 2008